EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Intra-articular allogeneic adipose-derived mesenchymal stromal cell injections for stage III knee osteoarthritis: a double-blind placebo-controlled trial with 60-month follow-up

Hanan Jafar iD, Osama Samara, Diana Shahin, Fadwa Daoud, Dana Al-Hattab, Aseel Samara, Lina Al Lawama, Mohammed Hamdan, Huda Qubbaj, Bareqa Salah, Abdalla Awidi iD

Stem Cells Translational Medicine · 27.04.2026 · 15 (5)

DOI: 10.1093/stcltm/szag018 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Stem Cells Translational Medicine, online erschienen am 29.04.2026. Verfasst von Hanan Jafar und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cell Therapy Center (CTC), The University of Jordan, Amman 11942, Jordan. Hauptthemen laut MEDLINE: Osteoarthritis, Knee, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells, Adipose Tissue. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The University of Jordan/Deanship of Scientific Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Knee osteoarthritis (KOA) is a progressive degenerative joint disease with limited treatment options that effectively modify disease progression. This study evaluates the safety and efficacy of allogeneic adipose-derived mesenchymal stromal cells (ADMSCs) injected under ultrasound guidance in patients with symptomatic stage III KOA. In this single-site, randomized, double-blind, placebo-controlled trial, patients were assigned to receive either 2 doses of allogeneic expanded ADMSCs, administered 2 weeks apart (Arm A, mean total dose: 69.58 × 106 ADMSCs), or 2 equal-volume normal saline injections (Arm B). Blinding was maintained for 12 months, after which follow-up of Arm A continued to 60 months. Treatment efficacy was assessed using normalized Knee Injury and Osteoarthritis Outcome Score and Western Ontario and McMaster Universities Osteoarthritis Index at 6, 12, 24, 36, 48, and 60 months, while magnetic resonance imaging (MRI) evaluations were performed at baseline and 12 months. A total of 29 subjects (21 in Arm A, 8 in Arm B) completed the study. Adverse events in Arm A were mild and transient, including localized pain and swelling. Patients in Arm A demonstrated significant improvements in clinical scores compared to baseline, with highly significant differences at 6, 12, 24, and 36 months (P < .0001). MRI assessments at 12 months revealed structural improvement (P < .02). However, clinical improvements declined steadily after 36 months, with scores nearing baseline at 60 months. These findings suggest that allogeneic ADMSC therapy is safe and provides sustained clinical and structural benefits for up to 3 years. Larger trials are needed to optimize dosing and assess long-term efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Osteoarthritis, KneeMesenchymal Stem Cell TransplantationMesenchymal Stem CellsAdipose TissueHumansDouble-Blind MethodFemaleInjections, Intra-ArticularMaleMiddle AgedFollow-Up StudiesTransplantation, HomologousAgedTreatment Outcome

Stichwörter der Autor:innen

cartilage regenerationcellular therapyknee osteoarthritismesenchymal stromal cellsregenerative medicine

Autor:innen und Institutionen

  • Cell Therapy Center (CTC), The University of Jordan, Amman 11942, Jordan.
  • Department of Radiology & Nuclear Medicine, School of Medicine, The University of Jordan, Amman 11942, Jordan.
  • Department of Radiology, Jordan University Hospital, Amman 11942, Jordan.
  • Computational Bioscience Research Center (CBRC), King Abdullah University of Science and Technology, Thuwal 23955-6900, Saudi Arabia.
  • KAUST Center of Excellence for Smart Health (KCSH), King Abdullah University of Science and Technology, Thuwal 23955-6900, Saudi Arabia.
  • School of Medicine, The University of Jordan, Amman 11942, Jordan.

ORCID-Profile: Hanan Jafar, Abdalla Awidi

Förderung

  • The University of Jordan/Deanship of Scientific Research

Zitieren

APA

Jafar, H., Samara, O., Shahin, D., Daoud, F., Al-Hattab, D., Samara, A., Al Lawama, L., Hamdan, M., Qubbaj, H., Salah, B., & Awidi, A. (2026). Intra-articular allogeneic adipose-derived mesenchymal stromal cell injections for stage III knee osteoarthritis: a double-blind placebo-controlled trial with 60-month follow-up. Stem Cells Translational Medicine, 15(5). https://doi.org/10.1093/stcltm/szag018

Vancouver

Jafar H, Samara O, Shahin D, Daoud F, Al-Hattab D, Samara A, et al. Intra-articular allogeneic adipose-derived mesenchymal stromal cell injections for stage III knee osteoarthritis: a double-blind placebo-controlled trial with 60-month follow-up. Stem Cells Translational Medicine. 2026;15(5). doi:10.1093/stcltm/szag018

BibTeX
@article{Jafar2026,
  author = {Jafar, Hanan and Samara, Osama and Shahin, Diana and Daoud, Fadwa and Al-Hattab, Dana and Samara, Aseel and Al Lawama, Lina and Hamdan, Mohammed and Qubbaj, Huda and Salah, Bareqa and Awidi, Abdalla},
  title = {Intra-articular allogeneic adipose-derived mesenchymal stromal cell injections for stage III knee osteoarthritis: a double-blind placebo-controlled trial with 60-month follow-up},
  journal = {Stem Cells Translational Medicine},
  year = {2026},
  volume = {15},
  number = {5},
  doi = {10.1093/stcltm/szag018}
}
Kostenlos starten →